

Original Article

Prevalence and Trends of Transfusion-Transmissible Infections and Study of Confidential Unit Exclusion among Blood Donors in Kurdistan Province of Iran

Mahtab Maghsoodlu¹M.D., Pejman Salehifar²M.Sc., Parisa Rahimzadeh²M.Sc. Woria Babahajian²M.Sc., Saylan Mohammadi²M.Sc., Serveh Babahajian²M.Sc. Masoumeh Souri²M.D., Mohammad Saied Karimian²M.D. Shirin Ferdowsi^{1,2*}Ph.D.

¹Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

ABSTRACT

Article history

Received 13 Sep 2017 Accepted 7 Feb 2018 Available online 18 Mar 2018

Key words

Confidential unit exclusion Donors Infection Kurdistan Transfusion-transmissible **Background and Aims:** Evaluation of the prevalence of transfusion-transmissible infections (TTIs) in blood donors is a valuable index of donor selection and blood safety. This study was conducted to explore the prevalence and trends of TTIs markers and study of confidential unit exclusion (CUE) option among blood donors in Kurdistan province in the west of Iran.

Materials and Methods: We conducted a cross-sectional analysis on all volunteer donors from 2007 to 2014. Serologic tests were performed to detect TTIs markers. The seropositive results were confirmed using the confirmatory assays.

Results: Of 197568 cases of the blood donated during 2007 and 2014, 0.29% was positive for Hepatitis B surface antigen, 0.006% for anti-human immunodeficiency virus and 0.06% for anti-hepatitis C virus. The prevalence of human immunodeficiency virus remained stably below 0.02% during the study period whereas the prevalence of Hepatitis B surface antigen showed a downward trend over the period of 8 years. The trend of hepatitis C virus infection frequency had increasing patterns from 2007 to 2009 and decreasing patterns thereafter to 0.05%. CUE was chosen in 1442 (0.7%) donations. Out of this number, 864 (59.9%) were first time blood donors and 578 (40.08%) repeat donors. CUE-positive donations had significantly higher risk of TTIs markers (p< 0.000).

Conclusions: The prevalence rate of viral infections has been reduced to low levels in blood donations over the 8 years. Moreover, CUE is considered an effective option for identifying donors with increased risk of TTIs markers.

²Kurdistan Blood Transfusion Organization, Sanandaj, Iran.

Introduction

One of the problems in providing safe blood units is the risk of transfusion-transmissible infections (TTIs). Viral infections such as hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV) are the greatest concerns [1]. Screening for TTIs is a routine practice to guarantee the safety of blood products. Moreover, monitoring the trends in the prevalence of TTIs in blood donors will provide a mechanism to evaluate the safety of the blood supply and the effectiveness of donor deferral criteria [2]. To improve the safety of the blood, other measures, such as the use of confidential unit exclusion (CUE), have also been adopted by many blood banks. The main goal of the CUE process is detecting donors who are infected but are in the window period. This process was designed for detecting donors who denied their involvement in high-risk activities during the pre-donation interview [2] and an opportunity to confidentially exclude their blood [3]. In 2015, World Health Organization (WHO) reported that the prevalence of HBV, HCV and HIV infections among donors varies from 0.008% to 6.08%, 0.004% to 1.96%, and 0.0004% to 2.0%, respectively in different parts of the world [4]. The prevalence of HBV, HIV and HCV infections in Iran is 0.7% [5], 0.004% [2] and 0.5% [6] in blood donors, respectively. Therefore, this study was conducted to report the prevalence and trends of TTIs infections and the prevalence of CUE among blood donors in Kurdistan province, west of Iran, during an eight-year period. To

our knowledge, this is the first report that extensively examines TTIs markers among the donor population in this part of Iran.

Materials and Methods

This study was conducted at the Kurdistan Blood Transfusion Center over a period of 8 years (between 2007 and 2014). All donors were classified as first time if they had a history of only one donation. Repeat donor status was defined as having donated more than once during the study period. Serologic tests were performed on all donations using commercial products to detect surface antigens of the HBV (HBsAg), antibodies against the HCV (anti-HCV) and antibodies against the HIV types 1 and 2 (anti-HIV 1/2). All initially positive samples were retested. These seropositive results were confirmed using the HBs Ag confirmatory assay, HIV I/II western blot, and HCV recombinant immunoblot assay. Regarding HIV, the HIV western blotnegative samples were further evaluated for the presence of HIV P24 antigen and the reactive samples were confirmed using the monoclonal neutralization assay (Table 1). In addition, the use of the CUE option was studied among the donors. The frequencies of the replies to the CUE were calculated in respect to gender, age and category of donation.

Statistical analysis

Statistical analysis was carried out using SPSS 16 software and comparisons were evaluated with Chi-square test.

Table 1. Kits used for donor screening, 2007-2014

| | | Screening test kits | | | | |
|----------------------|--|--|--|--|--|--|
| Year | HBsAg screening test kit | Anti-HCV screening test kit | HIV Ag/Ab screening test kit | | | |
| | (Manufacturer) | (Manufacturer) | (Manufacturer) | | | |
| | Enzygnost HBsAg 5.0 | HCV 3.0 with enhanced SAVe | Genscreen Plus HIV Ag-Ab | | | |
| 2007-2009 | (Dade Behring, Germany) | (Ortho- Clinical Diagnostics, USA), | (Bio-Rad, USA), | | | |
| | | Hepanostica Anti-HCV Ultra | Vironostika HIV Uni-Form II Ag/Ab | | | |
| | | (BioMerieux, France) | (BioMerieux, France) | | | |
| 2010 | Enzygnost HBsAg 5.0 | HCV 3.0 with enhanced SAVe | Genscreen Plus HIV Ag-Ab | | | |
| | (Dade Behring, Germany), | (Ortho- Clinical Diagnostics, USA), | (Bio-Rad, USA), | | | |
| | Enzygnost HBsAg 6.0 | Hepanostica Anti-HCV Ultra | Vironostika HIV Uni-Form II Ag/Ab | | | |
| | (Siemens, Germany) | (BioMerieux, France) | (BioMerieux, France) | | | |
| | | HCV 3.0 with enhanced SAVe | | | | |
| 2011 | Enzygnost HBsAg 6.0 | (Ortho- Clinical Diagnostics, USA), | EIAgen Detect HIV 4 Total Screening Kit | | | |
| | (Siemens, Germany) | Hepanostica Anti-HCV Ultra | (Adaltis, Canada) | | | |
| | | (BioMerieux, France) | | | | |
| 2012-2014 | Enzygnost HBsAg 6.0 | EIAgen HCV Ab test | EIAgen Detect HIV 4 Total Screening Kit | | | |
| | (Siemens, Germany) | (Adaltis Canada) | (Adaltis ,Canada) | | | |
| | | Confirmatory test kits | | | | |
| Year | HBsAg confirmatory test | HCV RIBA | HIV Western Blot | | | |
| TCar | (Manufacturen) | (Manufacturer) | (Manufacturer) | | | |
| | (Manufacturer) | | , | | | |
| | (Manufacturer) | | HIV Blot 2.2 | | | |
| 2007-2008 | HBsAg confirmatory test | MP Diagnostics HCV BLOT 3.0 | | | | |
| 2007-2008 | | MP Diagnostics HCV BLOT 3.0 (MP Biomedicals, USA) | HIV Blot 2.2 | | | |
| 2007-2008 | HBsAg confirmatory test | • | HIV Blot 2.2 (Genelabs diagnostics, Singapore), | | | |
| 2007-2008 | HBsAg confirmatory test | • | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 | | | |
| | HBsAg confirmatory test (Dade Behring, Germany) | (MP Biomedicals, USA) | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) | | | |
| 2007-2008 2009 | HBsAg confirmatory test (Dade Behring, Germany) HBsAg confirmatory test | (MP Biomedicals, USA) HCV Blot 3.0 | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) HIV Blot 2.2 | | | |
| | HBsAg confirmatory test (Dade Behring, Germany) HBsAg confirmatory test (Dade Behring, Germany), | (MP Biomedicals, USA) HCV Blot 3.0 | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) HIV Blot 2.2 (Genelabs diagnostics, Singapore), | | | |
| 2009 | HBsAg confirmatory test (Dade Behring, Germany) HBsAg confirmatory test (Dade Behring, Germany), HBsAg confirmatory test | (MP Biomedicals, USA) HCV Blot 3.0 | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 | | | |
| | HBsAg confirmatory test (Dade Behring, Germany) HBsAg confirmatory test (Dade Behring, Germany), HBsAg confirmatory test (Siemens, Germany) | (MP Biomedicals, USA) HCV Blot 3.0 (Genelabs diagnostics, Singapore) | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) | | | |
| 2009 | HBsAg confirmatory test (Dade Behring, Germany) HBsAg confirmatory test (Dade Behring, Germany), HBsAg confirmatory test (Siemens, Germany) HBsAg confirmatory test | (MP Biomedicals, USA) HCV Blot 3.0 (Genelabs diagnostics, Singapore) MP Diagnostics HCV BLOT 3.0 | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) MP Diagnostics HIV Blot 2.2 | | | |
| 2009 | HBsAg confirmatory test (Dade Behring, Germany) HBsAg confirmatory test (Dade Behring, Germany), HBsAg confirmatory test (Siemens, Germany) HBsAg confirmatory test (Siemens, Germany) | (MP Biomedicals, USA) HCV Blot 3.0 (Genelabs diagnostics, Singapore) MP Diagnostics HCV BLOT 3.0 (MP Biomedicals, USA) | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) | | | |
| 2009 2010 2011 | HBsAg confirmatory test (Dade Behring, Germany) HBsAg confirmatory test (Dade Behring, Germany), HBsAg confirmatory test (Siemens, Germany) HBsAg confirmatory test (Siemens, Germany) HBsAg confirmatory test | (MP Biomedicals, USA) HCV Blot 3.0 (Genelabs diagnostics, Singapore) MP Diagnostics HCV BLOT 3.0 (MP Biomedicals, USA) HCV Blot 3.0 | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) MP Diagnostics HIV Blot 2.2 | | | |
| 2009 2010 | HBsAg confirmatory test (Dade Behring, Germany) HBsAg confirmatory test (Dade Behring, Germany), HBsAg confirmatory test (Siemens, Germany) HBsAg confirmatory test (Siemens, Germany) HBsAg confirmatory test (Siemens, Germany) | (MP Biomedicals, USA) HCV Blot 3.0 (Genelabs diagnostics, Singapore) MP Diagnostics HCV BLOT 3.0 (MP Biomedicals, USA) HCV Blot 3.0 (Genelabs diagnostics, Singapore) | HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) HIV Blot 2.2 (Genelabs diagnostics, Singapore), MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) MP Diagnostics HIV Blot 2.2 (MP Biomedicals, USA) | | | |

Results

Blood donor population

Of the qualified donors during 2007 to 2014, 197568 individuals donated their blood; 71630 (36.2%) donations were from first-time donors and 125938 (63.74%) from individuals who had donated blood two or more times. A total of 176104 (89.13%) donors were male and 21464 (10.86%) were female. Totally, 33.84% of the donations (66892) were from individuals aged 25 to 35. An increase in repeat donors was identified from 47% in 2007 to 70.6% in 2014 (Fig. 1).

Prevalence and trends of TTIs in blood donors

The prevalence of HIV, HBV and HCV was observed to be 0.006% (12 donors), 0.29% (578 donors) and 0.06% (121 donors), respectively. In our study, the HBsAg and HCV Ab prevalence among blood donors indicated a downward trend over the period of eight years (Fig. 2). The prevalence of HIV

remained stable below 0.02% during the study period, whereas the prevalence of HBs Ag decreased from 0.45% to 0.2% between 2008 and 2014. Prevalence of confirmed HCV positive results in donating blood has also decreased from 0.08% in 2010 to 0.05% in 2014. Five donors had multiple infections: 4 donors were infected with HCV and HIV while another suffered from HBV and HCV infections. All the subjects were male, first time blood donor, with the mean age of 38 years and schooling below 12 years. When grouping (HCV, HIV, and HBV) by years, the percentage was decreasing from 2008 (0.54 %) to 2014 (0.26 %). During our study, most of the infection was HBsAg 578/711 (81.2%) followed by HCV 121/711 (17 %); the least was HIV 12/711 (1.6 %).




Fig. 1. Number of donors in Kurdistan province, 2007–2014




Fig. 2. Trends of HBV, HCV and HIV infections among blood donors in Kurdistan province, 2007-2014

Prevalence of TTIs in CUE-positive versus CUE negative donors

Over the 8 years, the CUE 'do not use my blood' option was chosen by 1442 (0.7%) donors. Out of this number, 864 (59.9%) were first time blood donors and 578 (40.08%) repeat donors. Table 2 displays the CUE frequency according to donation status, gender, age and education. CUE-positive

donations had significantly higher risk of TTIs markers (Table 3). The high frequencies of serological tests were obtained for the anti-HCV serologic marker (1.24%), followed by anti-HBV (0.69%). For the anti-HIV (0.2%) serological marker, frequencies were 0.2% in CUE-positive donors. Higher HCV seroprevalence among males compared to females was statistically significant (p<0.019).

Table 2. Confidential unit exclusion use by donor demographics

| Demographic characteristics | | CUE positive (n, %) | CUE negative (n, %) | p-value | |
|-----------------------------|------------------------------|---------------------|---------------------|---------|--|
| Donation | First-time | 864 (1.2%) | 70766 (98.79%) | 0.000 | |
| Status | Repeat | 578 (0.45%) | 125360(99.54%) | | |
| Gender | Female | 65 (0.3%) | 21399(99.69%) | 0.000 | |
| | Male | 1377 (0.78%) | 174727 (99.21%) | | |
| | ≥18 <25 | 202 (0.49%) | 40852 (99.50%) | 0.000 | |
| | ≥25 <35 | 748 (1.11%) | 66144 (98.88%) | | |
| Age | ≥35 <45 | 301 (0.58%) | 51671 (99.42%) | | |
| | ≥45 <55 | 137 (0.45%) | 30028 (99.54%) | | |
| | ≥55 <65 | 54 (0.72%) | 7431 (99.27%) | | |
| Education | Less than 12 years schooling | 1038 (0.74%) | 137706 (99.25%) | 0.592 | |
| Education | 12 or more years schooling | 404 (0.68%) | 58420 (99.31%) | | |
| Camaanina | HBV | 10 (0.69%) | 568 (0.28%) | 0.000 | |
| Screening test | HCV | 18 (1.24%) | 103 (0.05%) | | |
| | HIV | 3 (0.2%) | 9 (0.004%) | | |

CUE= confidential unit exclusion; HBV= hepatitis B virus; HCV= hepatitis C virus; HIV= human immunodeficiency virus

Table 3. Frequency of TTI markers between CUE-positive and CUE-negative donations, according to the type of donor

| Years | CUE | Donor status | | | HBs Ag | | | HCV Ab | | , | HIV Ag/Ab | | • |
|-------|-----|--------------|--------|---------|----------|----------|---------|----------|----------|---------|-----------|----------|---------|
| | | First Time | Repeat | p-value | Positive | Negative | p-value | Positive | Negative | p-value | Positive | Negative | p-value |
| 2007 | N | 12124 | 10734 | 0.165 | 84 | 22783 | 0.005 | 0 | 22867 | 0 | 0 | 22867 | 0 |
| 2007 | P | 56 | 37 | | 2 | 91 | | 0 | 93 | | 0 | 93 | |
| 2000 | N | 11407 | 12714 | 0.000 | 109 | 24012 | 0.541 | 20 | 24101 | 0.751 | 0 | 24121 | 0.000 |
| 2008 | P | 84 | 37 | | 1 120 | | 0 | 121 | | 2 | 119 | | |
| 2000 | N | 9599 | 16232 | 0.000 | 95 | 25740 | 0.040 | 18 | 25817 | 0.000 | 1 | 25834 | 0.936 |
| 2009 | P | 110 | 57 | | 1 | 166 | | 7 | 160 | | 0 | 167 | |
| 2010 | N | 8087 | 17291 | 0.000 | 73 | 25305 | 0.361 | 18 | 25360 | 0.000 | 0 | 25378 | 0 |
| 2010 | P | 79 | 64 | | 1 | 142 | | 4 | 139 | | 0 | 143 | |
| 2011 | N | 7977 | 17477 | 0.000 | 70 | 25384 | 0.222 | 19 | 25435 | 0.630 | 1 | 25453 | 0.912 |
| 2011 | P | 176 | 135 | | 2 | 309 | | 0 | 311 | | 0 | 311 | |
| 2012 | N | 7683 | 17396 | 0.000 | 47 | 25032 | 0.043 | 11 | 25068 | 0.728 | 1 | 25078 | 0.000 |
| 2012 | P | 167 | 108 | | 2 | 273 | | 0 | 275 | | 1 | 274 | |
| 2012 | N | 6664 | 15869 | 0.000 | 39 | 22494 | 0.153 | 9 | 22524 | 0.000 | 4 | 22559 | 0.870 |
| 2013 | P | 84 | 67 | | 1 | 150 | | 1 | 150 | | 0 | 151 | |
| 2014 | N | 7270 | 17295 | 0.000 | 51 | 24853 | 0.542 | 8 | 24896 | 0.000 | 2 | 24902 | 0.904 |
| | P | 108 | 73 | | 0 | 181 | | 6 | 175 | | 0 | 181 | |

TTI= transfusion-transmissible infections; CUE= confidential unit exclusion; HbsAg= hepatitis B surface antigen; HCV= hepatitis C virus; HIV= human immunodeficiency virus; N= negative; P= positive

Discussion

In this cross-sectional study, 197568 individuals who had donated blood between 2007 and 2014 at Kurdistan province were examined. The prevalence rate of 0.29% for HBV was observed that was lower than those reported in the previous studies in Iran, i.e., 0.56% between 2004-2007 [2], and 0.38% between 2005-2011 [7] but was higher than that of the recent report from south of Iran i.e., 0.15% between 2004-2014 [8]. The prevalence of HCV infection in our study was 0.06% that is lower than other regions in Iran, i.e., 0.13% between 2004–2007 [2], 0.11% between 2005-2011 [7] and 0.1% between 2004-2014 [8]. In addition, the prevalence of HIV infection was 0.006% that is similar to

previous studies from Iran, i.e., 0.0054% [7] and 0.004% [2, 8]. In Kurdistan Province, the prevalence of HIV remained stable below 0.02% during 2007-2014 whereas the prevalence of HBsAg and HCV decreased from 2009 to 2013. These findings are consistent with other reports in Iran. In Yazd province, the prevalence rate of hepatitis B, C and HIV infection decreased from 0.37%, 0.14% and 0% in 2004 to 0.14%, 0.05% and in 2010, respectively [9]. In a study in Tehran [10], the prevalence rate of HBV, HCV and HIV in donors indicated a decline from 0.423%, 0.139% and 0.011% in 2008 to 0.153%, 0.069 % and 0.009% in 2013. In a recent study in south of Iran [8], the seroprevalence rate of HBV and HCV from 2004 to 2014 showed decreasing trend from 0.46% to 0.06% and 0.329% to 0.045%, respectively, that was significant, whereas HIV infection had insignificant decline from 0.0173% in 2004 to 0.0028% in 2014. In our study, seroprevalence of TTIs was higher among male compared to female Kurdish donors. This finding may be due to the lower number of female donors. The majority of agegroup donors were those ranging from 26 to 35 years (33.8%). This differs from the data published by WHO which reported that 45% of donors were aged 25 or lower [11].

On the other hand, in the present study, the CUE was chosen in 1442 (0.7%) donations, most frequently by first-time blood donors (p<0.000), by men (p<0.000) and by donors between 26-35 years old (p<0.000). This rate of CUE is higher than the previous reports on CUE (0.15-0.38% range) in the developed countries [12, 13]. In fact, higher rates have been reported to occur in Iran (0.6-0.92%) in Tehran Blood Transfusion Center [14, 15] and Brazil (1.1-3.2%) (16-19). Our results

indicated that CUE-positive donations had significantly higher risk of TTIs markers (p<0.000). The association between CUE use and higher prevalence of serologic markers has been previously described [20-23]. In a study, Amini Kafi-Abad et al. [24] identified that CUE helps to enhance blood safety in Iran.

Conclusions

Totally, the low prevalence rate of TTIs in blood donors and its decreasing trends demonstrates that the effective safety procedures have been performed at the Kurdistan blood transfusion organization during these years. In Kurdistan province, an increase in repeat donations was observed from 47% in 2007 to 70.6% in 2014. In addition, the function of CUE is critical in improving blood safety.

Conflict of Interest

There is no conflict of interest in this article.

Acknowledgements

The authors acknowledge Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran and Kurdistan Blood Transfusion Organization, Sanandaj, Iran.

References

- [1]. Nwokeukwu HI, Nwabuko CO, Chuku A, Ajuogu E, Dorathy OA. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis in blood donors in a tertiary health facility in south eastern Nigeria. Hematology and Leukemia 2014; 2(1): 4.
- [2]. Amini Kafi-abad S, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion 2009; 49(10): 2214-220.
- [3]. Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion- transmitted infections among

- multitransfused patients in Iran: a review. Transfusion Med. 2007; 17(6): 425-33.
- [4]. WHO. Blood safety and availability WfsN, updated June 2015. Available at: http://www.who.int/mediacentre/factsheets/fs279/en/.
- [5]. Alizadeh S, Pakzad I, Sayehmiri K, Pakzad R, Darvishi P. Prevalence of Hepatitis B among Blood Donors in Iran: A Systematic Review and Meta-analysis. Asian J Biol Sci. 2014;7(2): 35-46.
- [6]. Khodabandehloo M, Roshani D, Sayehmiri K. Prevalence and trend of hepatitis C virus infection among blood donors in Iran: A systematic review and meta-analysis. J Res Med Sci. 2013; 18(8): 674.

- [7]. Pourfathollah AA. Changes in Frequency of HBV, HCV, HIV and Syphilis Infections among Blood Donors in Tehran Province 2005-2011. Arch Iran Med. 2014; 17(9): 613-20.
- [8]. Farshadpour F, Taherkhani R, Tajbakhsh S, Tangestani MG, Hajiani G, Sharifi N, et al. Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study. PloS one. 2016; 11(6): e0157615.
- [9]. Shahshahani HJ, Vaziri M, Mansouri F. Seven years trends in prevalence of transfusion-transmissible viral infections in Yazd blood transfusion organization. Iran J Ped Hematol Oncol. 2013;3(3): 119-24.
- [10]. Keshvari M, Sharafi H, Alavian SM, Mehrabadi H, Zolfaghari S. Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. Transfusion Apheresis Sci. 2015; 53(1): 38-47.
- [11]. Teo KSK, Saparudin MS, Zaini Z, Ahmad Morshidi M, Metassan N, Jaberudin R, et al. Transfusion transmissible infections in Brunei Darussalam: a blood donor study. Brunei Int Med J. 2011; 7(6): 321-27.
- [12]. O'Brien S, Fan W, Xi G, Yi QL, Goldman M. Evaluation of the confidential unit exclusion form: the Canadian Blood Services experience. Vox sang. 2010; 98(2): 138-44.
- [13]. Sümnig A, Konerding U, Kohlmann T, Greinacher A. Factors influencing confidential unit exclusions in blood donors. Vox sang. 2010; 98(3): e231-e40.
- [14]. Omidkhoda A, Gharehbaghian A, Jamali M, AhmadBeigi N, Hashemi SM, Rahimi A, et al. Comparison of the prevalence of major transfusion-transmitted infections among Iranian blood donors using confidential unit exclusion in an Iranian population: Transfusion-transmitted infections among Iranian blood donors. Hepat Mon. 2011; 11(1): 11-13.
- [15]. Farhadi E, Gharehbaghian A, Karimi G, Samiee S, Tavasolli F, Salimi Y. Efficacy of the confidential unit exclusion option in blood donors in Tehran, Iran, determined by using the nucleic Acid testing method in 2008 and 2009. Hepatitis monthly. 2011; 11(11): 907-12.

- [16]. de Almeida-Neto C, Liu J, Wright DJ, Mendrone-Junior A, Takecian PL, Sun Y, et al. Demographic characteristics and prevalence of serologic markers among blood donors who use confidential unit exclusion (CUE) in São Paulo, Brazil: implications for modification of CUE polices in Brazil. Transfusion 2011; 51(1): 191-97.
- [17]. Loureiro FCM, Di Lorenzo Oliveira C, Proietti ABFC, Proietti FA. Confidential donation confirmation as an alternative to confidential unit exclusion: 15 months experience of the hemominas foundation. Rev Bras Hematol Hemoter. 2011; 33(4): 263-67.
- [18]. Vogler IH, Saito M, Spinosa AA, Silva MCd, Munhoz E, Reiche EMV. Effectiveness of confidential unit exclusion in screening blood donors of the regional blood bank in Londrina, Paraná State. Rev Bras Hematol Hemoter. 2011; 33(5): 347-52.
- [19]. Maia CN, Ruas MdO, Urias EVR. Confidential unit exclusion at the Regional Blood bank in Montes Claros: Fundação Hemominas. Rev Bras Hematol Hemoter. 2012; 34(1): 17-20.
- [20]. Korelitz J, Williams A, Busch M, Zuck T, Ownby H, Matijas L, et al. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: the Retrovirus Epidemiology Donor Study. Transfusion. 1994; 34(10): 870-76.
- [21]. Petersen L, Lackritz E, Lewis W, Smith D, Herrera G, Raimondi V, et al. The effectiveness of the confidential unit exclusion option. Transfusion. 1994; 34(10): 865-69.
- [22]. Zou S, Notari I, Musavi F, Dodd R. Current impact of the confidential unit exclusion option. Transfusion. 2004; 44(5): 651-57.
- [23]. Chiewsilp P, Kitkornpan S, Stabunswadigan S, Iamsilp W, Suebsaeng C. Evaluation of donor self exclusion program. Southeast Asian J Trop Med Public Health. 1993; 24(S1): 130-32.
- [24]. Amini Kafi-Abad S, Shariati M, Moghaddam M. Confidential unit exclusion process and blood safety; the Iranian blood transfusion organization experience between March 2004 and September 2006. Vox Sang. 2007; 93(S1): 115.